Eupraxia Pharmaceuticals (EPRX) Stock Chart & Stock Price History → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free EPRX Stock Alerts $2.79 0.00 (0.00%) (As of 06/5/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrends Eupraxia Pharmaceuticals Stock Price Performance5 Day Performance+2.95%1 Month Performance-5.11% Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. EPRX Stock Chart for Thursday, June, 6, 2024 EPRX Chart by TradingView Eupraxia Pharmaceuticals Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/04/2024$2.70$2.79+3.20%$2.83$2.666,983 shs$76.01 million06/03/2024$2.71$2.70-0.37%$2.77$2.702,096 shs$73.66 million05/31/2024$2.76$2.71-1.81%$2.87$2.719,414 shs$73.93 million05/30/2024$2.78$2.76-0.72%$2.79$2.762,674 shs$75.30 million05/29/2024$2.81$2.78-1.07%$2.89$2.786,066 shs$75.84 million05/28/2024$2.85$2.81-1.40%$2.90$2.8110,618 shs$76.66 million Get the Latest News and Ratings for EPRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 05/27/2024$2.85$2.85$2.96$2.8325,800 shs$77.75 million05/24/2024$2.85$2.85$2.96$2.8325,866 shs$77.75 million05/23/2024$2.95$2.85-3.39%$3.07$2.8527,210 shs$77.75 million05/22/2024$2.88$2.95+2.43%$3.19$2.92269,386 shs$80.48 million05/21/2024$2.95$2.88-2.37%$2.95$2.88158,486 shs$78.57 million05/20/2024$2.94$2.95+0.34%$2.96$2.923,766 shs$80.48 million05/17/2024$2.95$2.94-0.34%$2.95$2.904,760 shs$80.20 million05/16/2024$2.98$2.95-1.01%$2.98$2.9516,303 shs$80.48 million05/15/2024$2.95$2.98+1.02%$3.00$2.905,131 shs$81.29 million05/14/2024$2.90$2.95+1.72%$2.95$2.901,199 shs$80.48 million05/13/2024$2.90$2.90$2.94$2.8819,007 shs$79.11 million05/10/2024$2.93$2.90-1.02%$3.00$2.9019,070 shs$79.11 million05/09/2024$2.90$2.93+1.03%$2.97$2.8851,160 shs$79.93 million05/08/2024$2.92$2.90-0.68%$2.94$2.8819,264 shs$79.11 million05/07/2024$2.86$2.92+2.10%$3.00$2.8612,654 shs$79.66 million05/06/2024$2.94$2.86-2.72%$2.92$2.855,732 shs$78.02 million05/03/2024$2.78$2.94+5.95%$2.94$2.798,730 shs$80.20 million05/02/2024$2.68$2.78+3.54%$2.88$2.685,445 shs$75.70 million05/01/2024$2.74$2.68-2.19%$2.69$2.685,003 shs$73.11 million04/30/2024$2.70$2.74+1.48%$2.74$2.656,609 shs$73.66 million04/29/2024$2.80$2.70-3.57%$2.83$2.7027,155 shs$73.66 million04/26/2024$2.85$2.80-1.75%$2.85$2.7410,574 shs$76.39 million04/25/2024$2.92$2.85-2.40%$2.88$2.826,008 shs$77.75 million04/24/2024$3.00$2.92-2.67%$2.95$2.8028,641 shs$79.66 million04/23/2024$3.01$3.00-0.33%$3.08$2.8125,900 shs$81.84 million04/22/2024$2.68$3.01+12.31%$3.07$2.7030,005 shs$82.11 million04/19/2024$2.51$2.68+6.77%$2.79$2.5621,239 shs$73.11 million04/18/2024$2.64$2.51-4.92%$2.59$2.486,930 shs$68.47 million04/17/2024$2.62$2.64+0.76%$2.73$2.642,999 shs$72.02 million04/16/2024$2.70$2.62-2.96%$2.76$2.5359,945 shs$71.47 million04/15/2024$2.72$2.70-0.75%$2.81$2.6515,783 shs$73.66 million04/12/2024N/A$2.72$2.82$2.6511,236 shs$0.00 Related Companies: CorMedix Stock Chart Nature's Sunshine Products Stock Chart Mersana Therapeutics Stock Chart ADC Therapeutics Stock Chart 23andMe Stock Chart Adlai Nortye Stock Chart Enanta Pharmaceuticals Stock Chart Atai Life Sciences Stock Chart Aquestive Therapeutics Stock Chart Immutep Stock Chart Receive EPRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:EPRX) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | Sponsored"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the big...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
